Tempus AI stretches rally as co and SoftBank launch AI healthcare JV
** Shares of genetics testing firm Tempus AI TEM.O, backed by SoftBank 9984.T, up ~7% early Thurs, adding to ~10% gain in prior session
** SoftBank has launched joint venture with Tempus aiming to analyze personal medical data with artificial intelligence to come up with treatment recommendations, CEO Masayoshi Son told a briefing in Tokyo on Thurs
** The cos expected to each put $93 mln into the JV, which is anticipated to close next month
** TEM shares have fallen in majority of sessions since their Jun 14 public debut and are still down ~20% from $37 IPO price
** On Weds, co said it received 510(k) clearance from the FDA for device using AI to help identify patients who may be at increased risk of atrial fibrillation
** On Tues, Tempus announced it will develop, investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hypertension as part of collaboration with United Therapeutics UTHR.O
** Led by Groupon GRPN.O co-founder Eric Lefkofsky, Tempus has never been profitable since its 2015 inception
** Rev from its "AI applications" business was about 1% of total rev of ~$532 mln in 2023, per SEC filing. Tempus described its AI Applications rev as "immaterial"
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
</body></html>
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
